1. Published

   Adverse drug reactions in economic evaluations

   Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109

   Research output: Contribution to journal › Article › peer-review

2. Published

   Adverse drug reactions in economic evaluations

   Hughes, D. & Hughes, D. A., 1 Mar 2007.

   Research output: Contribution to conference › Paper

3. Published

   Adverse drug reactions in economic evaluations

   Hughes, D. & Hughes, D. A., 1 Jul 2007.

   Research output: Contribution to conference › Paper

4. Published

   Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

   Osanlou, R., Walker, L., Hughes, D., Burnside, G. & Pirmohamed, M., 4 Jul 2022, In: BMJ Open. 12, 7, e055551.

   Research output: Contribution to journal › Article › peer-review

5. Published

   Adverse drug reactions: analysis by regulatory authorities and by economists

   Hughes, D. & Hughes, D. A., 1 Apr 2007.

   Research output: Contribution to conference › Paper

6. Published

   Affordable orphan drugs: A role for not-for-profit organisations

   Davies, E. H., Fulton, E., Brook, D. & Hughes, D., Jul 2017, In: British Journal of Clinical Pharmacology. 83, 7, p. 1595-1601

   Research output: Contribution to journal › Article › peer-review

7. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

   Research output: Book/Report › Commissioned report

8. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

   Research output: Book/Report › Commissioned report

9. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

   Research output: Book/Report › Commissioned report

10. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report